X-Pressure
X-Pressure is developing the XP One device, a novel medical technology aimed at improving the detection and management of Normal Pressure Hydrocephalus (NPH) through standardized cerebrospinal fluid (CSF) infusion tests. Leveraging 25 years of multicenter datasets and algorithms, the XP One provides real-time analysis of CSF outflow resistance at the bedside, enhancing physician decision-making. The device is designed to be plug-and-play, compatible with all lumbar puncture needles, and offers instant analysis via a portable tool, with secure digital platform monitoring that is HIPAA & GDPR compliant. The company's mission is to advance neurological care by enabling confident NPH detection and improving patient outcomes, addressing the significant issue that nearly 80% of NPH cases go undiagnosed or are misdiagnosed due to traditional imprecise assessment methods.
X-Pressure
X-Pressure is developing the XP One device, a novel medical technology aimed at improving the detection and management of Normal Pressure Hydrocephalus (NPH) through standardized cerebrospinal fluid (CSF) infusion tests. Leveraging 25 years of multicenter datasets and algorithms, the XP One provides real-time analysis of CSF outflow resistance at the bedside, enhancing physician decision-making. The device is designed to be plug-and-play, compatible with all lumbar puncture needles, and offers instant analysis via a portable tool, with secure digital platform monitoring that is HIPAA & GDPR compliant. The company's mission is to advance neurological care by enabling confident NPH detection and improving patient outcomes, addressing the significant issue that nearly 80% of NPH cases go undiagnosed or are misdiagnosed due to traditional imprecise assessment methods.
TL;DR
Headquarters: Toulouse, France
Product: XP One — bedside CSF infusion testing device for NPH
Founded: 2021
Last funding: Seed announced Jun 30, 2023
Employee count: 8
Company Overview
Problem Domain
Diagnosis and management of Normal Pressure Hydrocephalus (NPH) via cerebrospinal fluid (CSF) infusion testing.
Founded
2021
Industry
Medtech
Funding Track Record
Seed round announced June 30, 2023
Investor Signal
“Bpifrance; IRDI SORIDEC Gestion; M Capital Partners”